PriceTargets.com logo

Aardvark Therapeutics - AARD Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $31.50
  • Forecasted Upside: 178.02%
  • Number of Analysts: 4
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 4 Buy Ratings
  • 0 Strong Buy Ratings
$11.33 As of 05/1/2025 05:00 PM ET
▲ +0.22 (1.98%)

This chart shows the closing price for AARD by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
MarApr$11.33Closing price on 05/01/25:
Get New Aardvark Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for AARD and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for AARD

Analyst Price Target is $31.50
▲ +178.02% Upside Potential
This price target is based on 4 analysts offering 12 month price targets for Aardvark Therapeutics in the last 3 months. The average price target is $31.50, with a high forecast of $50.00 and a low forecast of $21.00. The average price target represents a 178.02% upside from the last price of $11.33.

This chart shows the closing price for AARD for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart
2/255/255/26$4.90$16$27$39$50Closing price on 05/01/25: $11.33High$50.00Average$31.50Low$21.00




Current Consensus is Buy

The current consensus among 4 investment analysts is to buy stock in Aardvark Therapeutics.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/8/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
2/6/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
5/6/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
8/4/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/2/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/31/2025
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/1/2025
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
5/1/2025

Latest Recommendations

  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
4/1/2025Royal Bank of CanadaReiterated RatingOutperform ➝ Outperform$21.00 ➝ $21.00
4/1/2025Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$50.00 ➝ $50.00
3/27/2025Bank of AmericaBoost TargetBuy ➝ Buy$22.00 ➝ $26.00
3/10/2025Morgan StanleyInitiated CoverageOverweight$29.00
3/10/2025Bank of AmericaInitiated CoverageBuy$22.00
3/10/2025Royal Bank of CanadaInitiated CoverageOutperform$21.00
3/10/2025Cantor FitzgeraldInitiated CoverageOverweight$50.00
(Data available from 5/1/2020 forward)

News Sentiment Rating

0.17 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/3/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/2/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/2/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/1/2025
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/31/2025
  • 1 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/2/2025
  • 2 very positive mentions
  • 8 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
4/1/2025
  • 0 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/1/2025

Current Sentiment

  • 0 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

  • No very positive mentions tracked during this time.
Aardvark Therapeutics logo
Aardvark Therapeutics, Inc. operates as a biotechnology company. It engages in the development of a novel small molecule therapeutics for obesity and metabolic diseases. The company was founded by Tien Lee in 2017 and is headquartered in San Diego, CA.
Read More

Today's Range

Now: $11.33
Low: $10.46
High: $11.57

50 Day Range

MA: $9.33
Low: $7.00
High: $13.65

52 Week Range

Now: $11.33
Low: $4.88
High: $19.58

Volume

171,760 shs

Average Volume

128,560 shs

Market Capitalization

$245.82 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Aardvark Therapeutics?

The following equities research analysts have issued research reports on Aardvark Therapeutics in the last year: Bank of America Co., Cantor Fitzgerald, Morgan Stanley, and Royal Bank of Canada.
View the latest analyst ratings for AARD.

What is the current price target for Aardvark Therapeutics?

0 Wall Street analysts have set twelve-month price targets for Aardvark Therapeutics in the last year. Their average twelve-month price target is $31.50, suggesting a possible upside of 178.0%. Cantor Fitzgerald has the highest price target set, predicting AARD will reach $50.00 in the next twelve months. Royal Bank of Canada has the lowest price target set, forecasting a price of $21.00 for Aardvark Therapeutics in the next year.
View the latest price targets for AARD.

What is the current consensus analyst rating for Aardvark Therapeutics?

Aardvark Therapeutics currently has 4 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe AARD will outperform the market and that investors should add to their positions of Aardvark Therapeutics.
View the latest ratings for AARD.

What other companies compete with Aardvark Therapeutics?

Other companies that are similar to Aardvark Therapeutics include Cronos Group, Replimune Group, Dianthus Therapeutics, Xeris Biopharma and KalVista Pharmaceuticals. Learn More about companies similar to Aardvark Therapeutics.

How do I contact Aardvark Therapeutics' investor relations team?

Aardvark Therapeutics' physical mailing address is 4370 LA JOLLA VILLAGE DRIVE, SUITE 1050, SAN DIEGO, CA, 92122. The company's listed phone number is (858) 225-7696. The official website for Aardvark Therapeutics is aardvarktherapeutics.com. Learn More about contacing Aardvark Therapeutics investor relations.